Goldman Sachs Maintains Neutral on RXO, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Neutral 59.4%

Neg 0% Neu 59.4% Pos 0%

Goldman Sachs analyst Jordan Alliger maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $18 to $20.